fda semaglutide warning september 2025 Semaglutide: The Drug of Today and a Steppingstone to Tomorrow

FDA has approved a new oral form of semaglutide for long-term weight reduction in adults with obesity or overweight. The new oral tablet is also indicated for reducing the risk of major

27.26

★★★★☆4.8 (126)

There's lots going on this month at FDA in the world of weight loss drugs. The agency is taking a hard look at the market. Check out these new #FDA Warning Letters

24.72

★★★★★4.9 (98)

FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in the U.S. drug supply chain. The agency recently seized dozens of units of counterfeit Ozempic (semaglutide) injection 1 mg that were

29.80

★★★★★5.0 (157)

FDA Drug Recalls and Warnings: Illegal GLP-1 Sales and Misleading Marketing by Novo Nordisk and Eli Lilly

20.32

★★★★★4.7 (84)

The FDA has issued a warning to Novo Nordisk over its alleged failure to report adverse side effects, including death, in patients who took its GLP-1 medications, popularly known as Ozempic and

21.17

★★★★★4.9 (203)

The FDA sent a warning letter to the maker of Ozempic and Wegovy over unreported potential GLP-1 side effects. Here's what to know

28.93

★★★★★5.0 (176)

The FDA has sent 30 warning letters to telehealth companies for falsely marketing compounded GLP-1s, which are not FDA-approved and can pose risks to patients. FULL STORY:🔗https://tinyurl.com/3ztf9uj2

29.71

★★★★★4.8 (132)